ORIGINAL ARTICLE

Cycles of transient high-dose cyclophosphamide administration and intratumoral oncolytic adenovirus vector injection for long-term tumor suppression in Syrian hamsters

D Dhar^{1,2}, K Toth¹ and WSM Wold¹

Immune responses against oncolytic adenovirus (Ad) vectors are thought to limit vector anti-tumor efficacy. With Syrian hamsters, which are immunocompetent and whose tumors and normal tissues are permissive for replication of Ad5-based oncolytic Ad vectors, treating with high-dose cyclophosphamide (CP) to suppress the immune system and exert chemotherapeutic effects enhances Ad vector anti-tumor efficacy. However, long-term CP treatment and immunosuppression can lead to anemia and vector spread to normal tissues. Here, we employed three cycles of transient high-dose CP administration plus intratumoral injection of the oncolytic Ad vector VRX-007 followed by withdrawal of CP. Each cycle lasted 4–6 weeks. This protocol allowed the hamsters to remain healthy so the study could be continued for ~100 days. The tumors were very well suppressed throughout the study. With immunocompetent hamsters, the vector retarded tumor growth initially, but after 3–4 weeks the tumors resumed rapid growth and further injections of vector were ineffective. Preimmunization of the hamsters with Ad5 prevented vector spillover from the tumor to the liver yet still allowed for effective long-term anti-tumor efficacy. Our results suggest that a clinical protocol might be developed with cycles of transient chemotherapy plus intratumoral vector injection to achieve significant anti-tumor efficacy while minimizing the side effects of cytostatic treatment.

Cancer Gene Therapy (2014) **21**, 171–178; doi:10.1038/cgt.2014.13; published online 11 April 2014

INTRODUCTION

Oncolytic adenovirus (Ad) vectors are emerging as a promising form of cancer therapy (reviewed in refs.^{1–5}). To be effective, oncolytic viruses need to infect and lyse cancer cells and, in theory, spread efficiently throughout the tumor. Two major barriers for efficient spread of the vector inside the tumor are hypothesized to include the tumor architecture (physical barrier)^{6,7} and the immune system (which clears the vector from the tumor site).^{8,9} We and others have employed the Syrian hamster as a model to study the anti-tumor efficacy, biodistribution and toxicity of oncolytic Ad Serotype 5 (Ad5)-based vectors (reviewed in refs.^{10,11}). The virtues of this model are that numerous Syrian hamster tumor cell lines exist that are permissive for Ad5 and that form tumors in hamsters, the tissues of the hamsters are permissive for Ad5 replication, and the hamsters are immunocompetent. Our long-term goals are to use this model to establish general principles and to develop protocols by which oncolytic Ad vectors can be used to treat cancer in humans.

We^{9,12,13} and others^{8,14–18} have shown that cyclophosphamide (CP) treatment of animals bearing tumors significantly increases vector anti-tumor efficacy following intratumoral injection of the vector as compared with the untreated counterpart. We used high-dose CP in our studies; the increased efficacy observed might be due to the immunosuppressive effect of CP that facilitates prolonged persistence and efficient spread of the vector inside the tumor.^{8,9,14} Further, noting that CP is a chemotherapeutic alkylating agent, we have reported that high-dose CP acts

additively with the Ad vector to control tumor growth.¹² In our studies, long-term treatment with CP leads to various side effects such as anemia and increased vector toxicity due to systemic vector spread and replication in normal tissues.⁹

To minimize the drawbacks of long-term treatment with CP and still achieve maximum anti-tumor efficacy, in the current study we have employed repeated cycles of transient treatment with CP and vector administration. Subcutaneous tumors were developed in Syrian hamsters using a hamster renal cancer cell line (HaK), then the hamsters were administered high-dose CP and the tumors were injected with the Ad5-based oncolytic vector VRX-007. Red blood cell (RBC) and white blood cell (WBC) levels were monitored, and the CP treatment was discontinued temporarily until the RBC recovered. Tumor growth was measured throughout the study. This protocol mitigated the adverse side effects of CP (for example, anemia) and allowed the study to proceed for ~100 days. VRX-007 is being evaluated in a phase I dose escalation clinical trial: intratumoral injection of VRX-007 into advanced solid tumors of any indication (Protocol #510-732). VRX-007 retains all Ad5 genes except those in the E3 region.

To investigate the role of preexisting immunity to Ad5 in vector anti-tumor efficacy and to restrict vector spillover from the tumor to normal tissues in hamsters immunosuppressed by CP in this long-term study, we immunized the hamsters with Ad5 before CP treatment. Preexisting immunity in the hamster model resembles the situation in many cancer patients inasmuch as most of the human population in the world has immunity to Ad5.¹⁹ We found

¹Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St Louis, MO, USA. Correspondence: Dr WSM Wold, Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, 1100 South Grand Boulevard, St Louis, MO 63104, USA.
E-mail: woldws@slu.edu

²Current address: Dr Dhar, Laboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, University of California, San Diego, School of Medicine, 9500 Gilman Drive, Leichtag Building, MC 0723, La Jolla, CA 92093, USA

Received 31 October 2013; revised 6 March 2014; accepted 10 March 2014; published online 11 April 2014

that tumor growth was effectively suppressed in the preimmunized hamsters and that preimmunization successfully prevented vector spillover and infection of the liver.

MATERIALS AND METHODS

Animals

Syrian (Golden) hamsters (*Mesocricetus auratus*; 4–5 weeks old) were obtained from Harlan Sprague Dawley (Indianapolis, IN). Saint Louis University Institutional Animal Care and Use Committee approved the studies. The studies were conducted in accordance with institutional and federal regulations.

Viruses and vectors

The oncolytic Ad vector VRX-007 is based on Ad5. VRX-007 lacks most of the E3 genes and overexpresses the E3-11.6K Adenovirus Death Protein.^{20,21} All other genes in VRX-007 are intact; despite this, VRX-007 replicates with about 100-fold greater yield in human A549 human lung cancer cells than in primary bronchial epithelial cells²² and it replicates poorly in quiescent versus proliferating primary human bronchial epithelial cells.²³ Introgen Therapeutics (Houston, TX) kindly provided us with the purified stocks.^{13,24} VRX-007 is named INGN 007 in some previous publications.

Immunization

Single intramuscular injection of Ad5 (1×10^{10} plaque forming units (p.f.u.)) was used to generate preexisting immunity in some groups of hamsters 15 days before injecting HaK cells to form tumors.¹³

Antitumor therapy: cycles of treatment with CP, intratumoral injection with VRX-007, and recovery from CP

Subcutaneous tumors were established in the hind flank of hamsters by injecting 2×10^7 hamster kidney cancer cells (HaK) in 200 μ l of serum-free DMEM.¹³ When the mean tumor volumes reached ~ 600 – 700 μ l, the treatment procedures started. Tumors of ~ 600 – 700 μ l are considerably larger than tumors typically studied in animal models using oncolytic viral vectors. The experimental groups are shown in Table 1. Some groups of hamsters were subjected to the cycles of CP treatment, intratumoral VRX-007 injection, then withdrawal from CP (see Figures 2 and 3). These hamsters were treated with CP (Sigma-Aldrich, St Louis, MO), and were housed in sterile caging and fed irradiated chow and antibiotic (Baytril Bayer HealthCare (Shawnee Mission, KS)) treated water.^{9,13,24} The initial dose of CP was 140 mg kg^{-1} body weight and the subsequent doses were 100 mg kg^{-1} twice weekly. About 1 week following the first injection of CP and coinciding with the third CP injection, when the hamsters were severely immunosuppressed, the tumors were administered 5 daily injections of VRX-007, 1×10^{10} p.f.u. per injection. The levels of RBC and WBC including lymphocytes were monitored by periodic analysis of complete blood counts throughout the length of the study. When the hamsters started to show signs of anemia (less than normal RBC), the CP was withdrawn and the hamsters were allowed to recover to normal RBC levels. This withdrawal period completed the cycle. Three cycles of CP treatment–VRX-007 intratumoral injection–withdrawal from CP were completed. The CP–VRX-007 treatment immunosuppression/

chemotherapy periods were ~ 18 – 24 days and the recovery periods were ~ 14 – 22 days. Tumor volumes were measured using digital calipers twice every week.

Histopathology

The tumors from each animal were fixed in 10% neutral-buffered formalin. After fixation, the tumors were trimmed, embedded in paraffin, sectioned ($5 \mu\text{m}$), and stained with hematoxylin-eosin. A Nikon Optiphot microscope (Nikon, Melville, NY) equipped with a Nikon DXM1200 digital camera and ACT-1 software (Nikon) was used to capture the images. To obtain a comprehensive view of the tumor, several images were taken from one end of the tumor section to the other end traversing through the center of the tumor. The images were then stitched together using Adobe Photoshop and Illustrator softwares.

Neutralization assay

Neutralization assay was performed as described previously.^{13,24} The neutralizing antibodies (NAb) titers were determined by the highest dilution of serum/tissue extract that resulted in at least 50% inhibition of cytopathic effect by 100 p.f.u. of VRX-007 assayed on A549 cells.

Virus quantification in tissues

The whole tumor and part of the right lateral lobe of the liver were collected at the time of killing. All the tissues were frozen immediately in liquid nitrogen and stored at -80°C . The tissues were weighed and processed as described elsewhere.^{13,25} The infectious virus titers were determined by tissue culture infectious dose 50% (TCID50) assay on A549 cells.^{13,25}

Statistical analysis

The overall treatment effect was determined by the Kruskal–Wallis test and the Mann–Whitney *U* test was used for pairwise comparisons. $P \leq 0.05$ was considered to be significant.

RESULTS

Kinetics of RBC, WBC and lymphocyte decline after treatment with CP, the recovery kinetics after withdrawal from CP, and the generation of neutralizing antibodies against VRX-007

Before beginning the tumor growth control study, namely cycles of CP and VRX-007 administration, we conducted an experiment to define the kinetics of RBC, WBC and lymphocyte decline after treatment with CP, the recovery kinetics of these cells after the hamsters were taken off CP, and the generation of NAb against VRX-007. One group of hamsters was subjected to one round of CP treatment (Figure 1a) and the second group received a second and third round of CP (Figure 1c). VRX-007 was injected intramuscularly after the first (Figure 1a) or the second (Figure 1c) round of CP and the response of NAb at various days was determined (Figures 1b and d).

The WBC (Figure 1a) and lymphocyte (not shown) counts declined very rapidly by day 10 following the first CP treatment, and the hamsters became severely immunosuppressed. The RBC counts remained within normal range at 10 days (Figure 1a).

The hamsters from the first group were allowed to recover partially from immunosuppression, then VRX-007 was injected at day 14 (that is, 14 days after the first injection of CP) (Figure 1a). Serum was collected at days 21, 31 and 42, and NAb titers were determined. As shown in Figure 1b, there was a moderate NAb response ($\sim 1:400$) at day 21 that increased to $1:760$ at day 42. Thus, the naïve lymphocytes that developed following withdrawal from CP were capable of mounting an NAb response against the vector after only 7 days following withdrawal from CP.

The second group of hamsters was subjected to three rounds of CP (Figure 1c). VRX-007 was injected at day 42, during the lymphocyte recovery period following the second round of CP (Figure 1c). At 7 days following VRX-007 injection, the hamsters were treated a third time with CP, and the lymphocytes declined

Table 1. Groups of hamsters involved in the experiment described in Figure 3

Immune status	Addition of CP	Group name	
		Buffer groups	VRX-007 groups
Immune	+	Imm + CP + Buffer	Imm + CP + 007
	–	Imm + Buffer	Imm + 007
Non Immune	+	-----	NonImm + CP + 007
	–	-----	NonImm + 007

Abbreviation: CP, cyclophosphamide.

Figure 1. Cycle(s) of transient treatment with high-dose cyclophosphamide and recovery, and NAb response by the recovering white blood cell (WBC). (a, c) Kinetics of red blood cell (RBC) and WBC suppression and recovery in hamsters undergoing cycles of cyclophosphamide (CP) treatment and recovery. (b, d) Serum NAb titers. VRX-007 was injected intramuscularly (1×10^{10} plaque forming units (p.f.u.) per hamster) during the initial phase of recovery after either the first (a) or second (c) cycle of CP treatment. Serum NAb titers were plotted as the reciprocal of the highest dilution of serum that resulted in at least 50% inhibition of cytopathic effect when incubated with 100 p.f.u. of VRX-007. The bar through the triangles indicates the mean NAb value.

again. A good NAb response was observed at day 49 ($\sim 1:1920$) that probably was generated by lymphocytes between day 41 and 49 when CP was administered again. Little or no NAb was detected by day 60 (Figure 1d).

Importantly, the RBC levels for the most part recovered when the CP was withdrawn (Figures 1a and c). As such, the hamsters did not become anemic.

In summary, the levels and function of RBC and lymphocytes can be controlled by using rounds of CP treatment. Lymphocytes formed following CP withdrawal are able to generate NAb within 7 days of VRX-007 intramuscular injection.

Design of the long-term tumor growth control study

We next conducted the tumor growth control study being guided in part by the findings from Figure 1. As part of the study, we wished to evaluate the anti-tumor efficacy of intratumoral VRX-007 in immunocompetent hamsters, the anti-tumor efficacy of cycles of treatment with CP and VRX-007, whether the cycling of CP mitigated anemia, whether cycling controlled the levels of WBC, and the role of preexisting NAb to the vector. Six groups of hamsters bearing subcutaneous HaK tumors were established. The nature of these groups is depicted in Table 1. These groups and the results obtained will be described in the following sections.

The procedure used for the multiple cycles of transient treatment with CP followed by VRX-007 intratumoral administration is shown in Figures 2 and 3 and is described in the legend of Figure 3. The study lasted ~ 100 days following the first treatment with CP. During the entire study the RBC and WBC levels were monitored closely (Figure 2), and were used to determine the duration of CP treatment and the recovery period. The tumor growth measurements are in Figure 3. For ease of presentation and discussion, the cumulative tumor growth is shown after the

first (Figure 3a), second (Figure 3b) and third (Figure 3c) cycles of CP and vector administration. Tumors from an arm of the experiment were harvested at days 43, 74 and 90 and the NAb titers and the amount of VRX-007 in the tumors were determined (Figure 4). Histopathology of typical hematoxylin-eosin-stained tumors at day 46 is in Figure 5.

VRX-007 is effective for a period in immunocompetent hamsters, but then tumor regrowth occurs and a second series of vector injection is not effective

As shown in Figure 3a, growth of tumors was rapid in preimmunized hamsters that were immunocompetent and treated with buffer alone (Imm + Buffer) or hamsters that were immunosuppressed with CP and treated with buffer (Imm + CP + Buffer). The CP treatment retarded tumor growth slightly, but it was not statistically significant ($P = 0.347$) (Figure 3a). The buffer-injected groups were terminated at 28 days because of their large tumor burden.

Injection of VRX-007 into tumors of immunocompetent hamsters (NonImm + 007, Imm + 007) retarded tumor growth for 3–4 weeks compared with the buffer control ($P = 0.005$) (Figure 3a). However, the vector-injected tumors then began to grow rapidly (Figure 3b). Notably, a second round of intratumoral vector injection (5 consecutive daily injections of 1×10^{10} p.f.u. per injection, at days 29–33) did not affect the increased tumor growth rate (Figure 3b). These hamsters were terminated at day 46.

It is important to understand why VRX-007 ceased to be effective in these immunocompetent hamsters. One reason could be vector elimination by NAb. Indeed, anti-Ad5 NAb was very high in the tumors at day 43 ($\sim 1:40960$ in the Imm + 007 group, $\sim 1:10240$ in the Non-Imm + 007 group) (Figure 4a). Not

Figure 2. Suppression and recovery of white blood cell (WBC) and red blood cell (RBC) during the tumor efficacy study shown in Figure 3. Blood was collected from the hamsters periodically throughout the tumor efficacy study (Figure 3) and WBC (a) and RBC (b) levels were determined.

surprisingly from these high NAb levels, vector could not be detected in the tumors of these groups (Figure 4b). Those tumors from animals that were not treated with CP contained mostly viable cells (Figure 5, top two panels), indicating that the tumors were growing rapidly.

CP plus VRX-007 can be administered in multiple cycles and are strongly suppressive of tumor growth

The following discussion pertains to the groups treated with CP plus vector. First, considering the preimmunized group (Imm + CP + 007), at 28 days, the tumors grew faster than for the NonImm + CP + 007 group ($P=0.015$) (Figure 3a). This lesser vector efficacy in the Imm + CP + 007 group was likely due to the presence of NABs inside the tumor at the time of vector administration as described in our previous studies.¹³

After the second cycle of CP treatment–vector injection–recovery, tumors in both CP groups (Imm + CP + 007 and NonImm + CP + 007) were controlled much better than the tumors in the non-CP groups injected with VRX-007 ($P=0.000$) (Figure 3b). Clearly, the combination of high-dose CP treatment plus vector is much superior to either CP alone or vector alone. The question arises whether CP is enhancing vector replication and persistence though CP's immunosuppressive activity and/or whether CP is acting as a chemotherapeutic agent.

It is noteworthy that after the second cycle of CP–vector injection–recovery the tumors in the Imm + CP + 007 group were controlled equally as well as in the NonImm + CP + 007 group ($P=0.581$) (Figure 3b). As shown in Figure 4a, at day 43, NAb was found in the tumors of the Imm + CP + 007 group ($\sim 1:320$) and the NonImm + CP + 007 group ($\sim 1:40$). No vector was detected in the tumors of these groups. It should be noted that the data in Figures 4a and b are from tumors collected 14 days after the last vector injection, and also that the tumors at this point consisted mostly of necrotic areas and with limited patches of viable cells (see Figures 5c and d). No doubt there was vector in the tumors at the time of injection; the lack of vector in the tumors at day 43 is probably due to a combination of vector neutralization by NAb and a paucity of viable cells in the tumors from the CP-treated hamsters in which the vector can replicate. In any case, the suppression of tumor growth in the absence of vector suggests that CP is having a chemotherapeutic effect over the period days 28–46.

Starting at about day 65, tumors in both CP + vector groups started to grow again (Figure 3c). This could be because the tumors were devoid of vector (that is, there was no vector at day 43, see Figure 4b). Also, the hamsters had been off CP for 18 days, so any chemotherapeutic effect due to CP might be waning. A third cycle of CP treatment was administered at days 63–88, and vector was injected for a third round at days 69–73 (Figure 3c). This CP + vector treatment seemed to stop the regrowth of tumors and cause a decrease in tumor size (Figure 3c). Measurement of tumors continued until day 90 following the first injection of vector. Remarkably, the tumors in both CP-treated groups were controlled very well and equally well ($P=0.190$) with a tumor volume almost equal to the starting volume. Again, the question arises, what is responsible for retarding the tumor growth: the vector, CP or both? At day 74, 1 day after the last injection of vector in the third cycle of vector injection, high levels of vector (10^8 TCID₅₀ units) were detected in the tumors of the NonImm + CP + 007 group, and much lower levels ($\sim 10^3$ TCID₅₀ units) in the Imm + CP + 007 group (Figure 4d). At day 90, 18 days after the last injection of vector, vector ($\sim 10^5$ TCID₅₀ units) continued to be isolated from tumors in the NonImm + CP + 007 group, but not from the Imm + CP + 007 group (Figure 4f). The tumors of the Imm + CP + 007 group seemed to have more NAb than the NonImm + CP + 007 group at day 74 (Figure 4c) and day 90 (Figure 4e), and that could explain why the Imm + CP + 007 tumors had less vector. In any case, considering that the NonImm + CP + 007 group had the most vector in the tumor yet had similar growth suppression as the Imm + CP + 007 group, it seems possible that the tumor growth suppression may be due to CP chemotherapy. However, the vector injected at days 69–73 likely contributed as well to suppression of tumor growth.

Even though the tumors in the hamsters were very well controlled, some animals died during the late phases of the study. Upon necropsy, it was found that the subcutaneous tumor had metastasized to several tissues such as lungs and kidney that might be the reason for the deaths (Supplementary Figure 1). Therefore, we terminated the experiment at day 90 post first vector injection.

Figure 5 shows the histopathology analysis of representative tumors at day 46 of the experiment. The tumors from the non-CP-treated groups appeared to have viable cells (purple stained cells) throughout much of the tumor (Figures 5a and b), which explains why these tumors were growing rapidly (Figure 3b). As discussed, the high NAB in these tumors likely eliminated the vector. The tumors from the CP + VRX-007 groups had very few viable cells and large necrotic areas after the second cycle (Figures 5c and d) and also after the third cycle (data not shown). The paucity of viable cells in these latter tumors may explain why these tumors had little vector remaining (Figure 4b) from the last injection of vector 10 days previously, and why these tumors were growing

Figure 3. VRX-007 effectively suppresses subcutaneous tumor growth for 3–4 weeks in immunocompetent hamsters. Cycles of cyclophosphamide (CP) plus intratumoral VRX-007 administration plus recovery allow for long-term tumor growth control. Established HaK tumors in immunocompetent hamsters or hamsters undergoing cycles of CP treatment and recovery were injected with buffer or VRX-007. Both buffer groups were preimmunized by intramuscular injection with Ad5; then, one group was treated with CP (Imm + CP + Buffer) while the other group was not treated with CP (Imm + Buffer). With the VRX-007 groups, one was previously immunized with Ad5 (Imm + 007) while the other was immunized, treated with CP, then the tumors were injected with VRX-007 (Imm + CP + 007). Another group was not preimmunized before intratumoral injection of VRX-007 (NonImm + 007). The final group was not preimmunized, was treated using CP, then was injected intratumorally with VRX-007 (NonImm + CP + 007). A total of three cycles of CP treatment–recovery–vector injection were performed, as follows. Hamsters bearing subcutaneous HaK tumors were treated with CP at various time points as indicated. At day 0, VRX-007 was injected intratumorally (five consecutive daily injections, 1×10^{10} plaque forming units (p.f.u.) per injection). The CP treatment was stopped at day 10; at this time the white blood cell (WBC) and red blood cell (RBC) levels had dropped below normal and the hamsters were severely immunosuppressed (Figure 2). The hamsters were left without CP treatment for 14 days, at which time they mostly had normal RBC and WBC levels (day 24) (Figure 2). The first cycle was completed at this point. Then, the hamsters were treated with CP for a second cycle (days 24–42) and the vector was injected again (days 29–33), followed by recovery to near normal RBC and WBC levels (days 43–66) (Figure 2). At this point, two cycles of ‘CP treatment–vector injection–recovery’ had been performed. Then, a third cycle of CP treatment (days 66–87) and vector injection (days 68–72) was administered but without the final recovery period. The tumors were measured with digital calipers twice every week and the mean tumor volume for each group is shown after the first cycle (a), second cycle (b) and the third cycle (c). Other data from this experiment are shown in Figures 2, 4 and 5.

slowly, if at all. Notably, the tumor mass that we were measuring using digital calipers (Figure 3) in the hamsters that underwent cycling comprised mainly dead tissue.

Serum neutralizing antibodies prevent VRX-007 spillover from the tumor to the liver

We investigated whether serum NAb could minimize vector spillover from tumors. As shown in Figure 4g for the Imm + CP + 007 group, preimmunization effectively prevented vector spillover from the tumor to the liver at all time points (days 43, 74 and 90). The naïve hamsters (NonImm + CP + 007), on the other hand, had vector in the liver: $\sim 10^6$ TCID₅₀ per gram of liver at day 43 and $\sim 3 \times 10^4$ TCID₅₀ per gram of liver at day 74 (Figure 4g). No vector was detected in the liver at day 90 (kill).

DISCUSSION

A notable aspect of our results is that, in immunocompetent hamsters, VRX-007 injected intratumorally is able to retard tumor growth for 3–4 weeks, but then tumors start to grow rapidly. A second round of vector injection has no effect on tumor growth, probably because there are high levels of NAb in the tumor. These results are important considering that clinical protocols usually recommend multiple rounds of vector injection into patients that are for the most part immunocompetent.^{26,27}

Another notable aspect of our results is that the combination of intratumoral injection with VRX-007 plus high-dose CP treatment is much more effective at suppressing tumor growth than either VRX-007 alone or CP alone. With our cycling protocol, we were able to achieve very effective long-term control of tumor growth

due to aggressive virotherapy (high dose of VRX-007) and chemotherapy (high dose of CP), while mitigating, at least to some degree, the toxic effects of high-dose CP. This tumor growth suppression was achieved even though the starting tumors were large (600–700 μ l) and vascularized.

Another aspect of our results is that preimmunization of the hamsters with Ad5 did not affect the long-term anti-tumor efficacy of the VRX-007 + CP combination. Importantly, preimmunization was able to prevent spillover of VRX-007 from the tumors to the liver over the course of 90 days following first intratumoral injection of vector in the hamsters that were treated with CP.

CP has been employed by a number of laboratories to increase the anti-tumor efficacy and/or to decrease the immune response to oncolytic vectors including those based on Ad,^{9,12,13,15,24,28,29} herpes simplex virus type 1,^{8,16} reovirus,¹⁴ measles virus,^{17,30} vesicular stomatitis virus³⁰ and vaccinia virus.¹⁸ A variety of CP doses and dosing regimes have been used, usually in mouse models. Peng et al³⁰ concluded that 120 mg kg^{−1} of CP given daily by intraperitoneal injection for 4 days was a good regime to control the humoral response to intravenously administered oncolytic measles virus or vesicular stomatitis virus, but they did not study suppression of tumor growth. They noted that this regime was similar to CP dosing regimes used in humans for chemotherapy of cancer. With oncolytic Ads in the Syrian hamster tumor model, low-dose CP, for example, 20 mg kg^{−1} intraperitoneally twice per week³¹ or 300 or 500 mg kg^{−1} given once intraperitoneally,²⁸ has been used as a means to specifically delete regulatory T cells. Low-dose CP, for example, metronomic dosing of 50 mg kg^{−1}, has been used in cancer patients in combination with oncolytic Ad vectors.^{28,31} Another laboratory¹⁵ working with

Figure 4. Tumor NAb and tissue culture infectious dose 50% (TCID50) titers. NAb titers present in the tumor were determined by a neutralization assay with the tumor lysate after two cycles (**a**), after three cycles (**c**) and at killing (**e**). Infectious virus in the tumor was determined by TCID50 assay with tumor lysates after two cycles (**b**), after three cycles (**d**), and at killing (**f**). These data are from an arm of the experiment shown in Figure 3. (**g**) Preexisting immunity prevents vector spillover from the site of injection to the liver. Liver was collected from the vector-injected hamsters undergoing cycles of cyclophosphamide (CP) treatment–recovery (Figure 3) at various time points and TCID50 titers were determined.

Figure 5. Most of the tumor is non-viable in VRX-007-injected hamsters undergoing cycles of cyclophosphamide (CP) treatment–recovery and vector injection. Hematoxylin-eosin (H&E)-stained tumor sections from the experiment in Figure 3 are shown after the second cycle (day 46). Each panel shows a series of photographs stitched together to show the area through the center axis of the tumor starting from one end of the tumor to the other. Representative tumors from the groups that were not immunosuppressed but underwent two cycles of vector injection are shown in (a) (NonImm + 007) and (b) (Imm + 007). Representative tumors from groups that underwent two cycles of CP treatment–vector injection are shown in (c) (NonImm + CP + 007) and (d) (Imm + CP + 007). Viable nuclei show up as purple dots, while the homogenous pink staining represents necrotic areas in the tumor.

an oncolytic Ad vector in the Syrian hamster model reported the successful use of intermediate-dose CP (37 mg kg^{-1} , twice weekly) as well as the high-dose regime used in our current study. As discussed above, high-dose CP administered to animal models is toxic. However, our results reported here suggest that cycles of transient chemotherapy (and immunosuppression) using CP and vector intratumoral administration is a promising approach, one that has not been attempted previously in an immunocompetent animal model that is permissive for replication of oncolytic Ad vectors. The procedure allowed us to control the tumor growth and to keep the hamsters healthier for a much longer time than in previous studies.

We speculate from our results that a clinical protocol might be developed with cycles of transient chemotherapy coupled with multiple rounds of intratumoral vector injection to achieve significant antitumor efficacy while minimizing the side effects of chemotherapy and vector. Chemotherapy regimens involve repeated cycles of dosing of the chemotherapy drug followed by recovery similar to the protocol employed by us in the current study. We used high-dose CP, but an intermediate dose such as 37 mg kg^{-1} , twice weekly, might be sufficient.¹⁵ Also, other chemotherapeutic agents could work as well as many of these cause transient immunosuppression. To prevent vector spread, patients could either be immunized with a replication-defective Ad before the treatment, screened for preexisting anti-Ad NAb, or patients could be passively immunized with anti-Ad NAb.²⁴ Chemotherapy has shown to increase the vector efficacy when used together.³²

CONFLICT OF INTEREST

The VRX-007 vector, which is owned by VirRx, is being evaluated in a Phase I clinical trial. WSMW and KT own stock in VirRx.

ACKNOWLEDGEMENTS

We thank Jacqueline F Spencer for her help in bleeding the animals. This research was supported by grant CA118022 to WSMW from the National Institutes of Health.

REFERENCES

- Wold WSM, Ison MG. Adenoviruses. In: Knipe DM, Howley PM editors. *Fields Virology*, 6th edition. Lippincott Williams & Wilkins: Philadelphia, PA, 2013 1732–1767.
- Eager RM, Nemunaitis J. Clinical development directions in oncolytic viral therapy. *Cancer Gene Ther* 2011; **18**: 305–317.
- Toth K, Dhar D, Wold WSM. Oncolytic (replication-competent) adenoviruses as anticancer agents. *Expert Opin Biol Ther* 2010; **10**: 353–368.
- Pesonen S, Kangasniemi L, Hemminki A. Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data. *Mol Pharm* 2011; **8**: 12–28.
- Shi J, Zheng D. An update on gene therapy in China. *Curr Opin Mol Ther* 2009; **11**: 547–553.
- Ganesh S, Gonzalez EM, Idamakanti N, Abramova M, Vanroey M, Robinson M *et al*. Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice. *Cancer Res* 2007; **67**: 4399–4407. [Erratum appears in *Cancer Res* 2007; **67**(12):5998].
- McKee TD, Grandi P, Mok W, Alexandrakos G, Insin N, Zimmer JP *et al*. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. *Cancer Res* 2006; **66**: 2509–2513.
- Fulci G, Breyman L, Gianni D, Kurozumi K, Rhee SS, Yu J *et al*. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. *Proc Natl Acad Sci USA* 2006; **103**: 12873–12878.
- Thomas MA, Spencer JF, Toth K, Sagartz JE, Phillips N, Wold WSM. Immunosuppression enhances oncolytic adenovirus replication and anti tumor efficacy in the Syrian hamster model. *Mol Ther* 2008; **16**: 1665–1673.
- Wold WS, Toth K. Chapter three—Syrian hamster as an animal model to study oncolytic adenoviruses and to evaluate the efficacy of antiviral compounds. *Adv Cancer Res* 2012; **115**: 69–92.
- Dhar D, Toth K, Wold WSM. Syrian hamster tumor model to study oncolytic Ad5 based vectors. In: Kirn D, Liu TC, Thorne S editors. *Oncolytic Viruses: Methods and Protocols*. Humana Press: New York, 2012; **797**: 53–63.
- Young BA, Spencer JF, Ying B, Tollefson AE, Toth K, Wold WSM. The role of cyclophosphamide in enhancing antitumor efficacy of an adenovirus oncolytic vector in subcutaneous Syrian hamster tumors. *Cancer Gene Ther* 2013; **20**: 521–530.
- Dhar D, Spencer JF, Toth K, Wold WSM. Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters. *J Virol* 2009; **83**: 2130–2139.
- Qiao J, Wang H, Kottke T, White C, Twigger K, Diaz RM *et al*. Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. *Clin Cancer Res* 2008; **14**: 259–269.

- 15 Hasegawa N, Abei M, Yokoyama KK, Fukuda K, Seo E, Kawashima R *et al*. Cyclophosphamide enhances antitumor efficacy of oncolytic adenovirus expressing uracil phosphoribosyltransferase (UPRT) in immunocompetent Syrian hamsters. *Int J Cancer* 2013; **133**: 1479–1488.
- 16 Ikeda K, Ichikawa T, Wakimoto H, Silver JS, Deisboeck TS, Finkelstein D *et al*. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. *Nat Med* 1999; **5**: 881–887.
- 17 Ungerechts G, Springfield C, Frenzke ME, Lampe J, Parker WB, Sorscher EJ *et al*. An immunocompetent murine model for oncolysis with an armed and targeted measles virus. *Mol Ther* 2007; **15**: 1991–1997.
- 18 Lun XQ, Jang JH, Tang N, Deng H, Head R, Bell JC *et al*. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide. *Clin Cancer Res* 2009; **15**: 2777–2788.
- 19 Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J. Immune responses to adenovirus and adeno-associated virus in humans. *Gene Ther* 1999; **6**: 1574–1583.
- 20 Doronin K, Toth K, Kuppuswamy M, Krajcsi P, Tollefson AE, Wold WSM. Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus. *Virology* 2003; **305**: 378–387.
- 21 Tollefson AE, Scaria A, Hermiston TW, Ryerse JS, Wold LJ, Wold WSM. The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. *J Virol* 1996; **70**: 2296–2306.
- 22 Kuppuswamy M, Spencer JF, Doronin K, Tollefson AE, Wold WS, Toth K. Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression. *Gene Ther* 2005; **12**: 1608–1617.
- 23 Toth K, Kuppuswamy M, Shashkova EV, Spencer JF, Wold WSM. A fully replication-competent adenovirus vector with enhanced oncolytic properties. *Cancer Gene Ther* 2010; **17**: 761–770.
- 24 Dhar D, Spencer JF, Toth K, Wold WSM. Pre-existing immunity and passive immunity to Adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian Hamster Model. *Mol Ther* 2009; **17**: 1724–1732.
- 25 Thomas MA, Spencer JF, Wold WSM. Use of the Syrian hamster as an animal model for oncolytic adenovirus vectors. *Methods Mol Med* 2007; **130**: 169–183.
- 26 Chiocca EA, Abbed KM, Tatter S, Louis DN, Hochberg FH, Barker F *et al*. A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. *Mol Ther* 2004; **10**: 958–966.
- 27 Galanis E, Okuno SH, Nascimento AG, Lewis BD, Lee RA, Oliveira AM *et al*. Phase-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. *Gene Ther* 2005; **12**: 437–445.
- 28 Cerullo V, Diaconu I, Kangasniemi L, Rajeci M, Escutenaire S, Koski A *et al*. Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic Adenovirus. *Mol Ther* 2011; **19**: 1737–1746.
- 29 Lamfers ML, Fulci G, Gianni D, Tang Y, Kurozumi K, Kaur B *et al*. Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging. *Mol Ther* 2006; **14**: 779–788.
- 30 Peng KW, Myers R, Greenslade A, Mader E, Greiner S, Federspiel MJ *et al*. Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses. *Gene Ther* 2013; **20**: 255–261.
- 31 Koski A, Kangasniemi L, Escutenaire S, Pesonen S, Cerullo V, Diaconu I *et al*. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. *Mol Ther* 2010; **18**: 1874–1884.
- 32 Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L *et al*. A controlled trial of intratumoral ONYX-015, a selectively replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. *Nat Med* 2000; **6**: 879–885.

Supplementary Information accompanies the paper on Cancer Gene Therapy website (<http://www.nature.com/cgt>)